Abstract:Purpose: A dearth in pediatric drug development often leaves pediatricians with no alternative but to prescribe unlicensed or off-label drugs with a resultant increased risk of adverse events. We present the current status of pediatric drug development and, based on our data analysis, clarify the problems in this area. Further action is proposed to improve the drug development that has pediatric therapeutic orphan status. Methods: We analyzed all Phase II/III and Phase III trials in ClinicalTrials.gov that only included pediatric participants (<18 years old) between 2006 and 2014. Performance index, an indicator of pediatric drug development, was calculated by dividing the annual number of pediatric clinical trials by million pediatric populations acquired from Census.gov. Effects of the 2 Japanese premiums introduced in 2010, for the enhancement of pediatric drug development, were analyzed by comparing mean performance index prepremiums (2006-2009) and postpremiums (2010-2014) among Japan, the European Union, and the United States. The European Union Clinical Trials Register and published reports from the European Medicines Agency were also surveyed to investigate the Paediatric Committee effect on pediatric clinical trials in the European Union. Findings: Mean difference of the performance index in prepremiums and postpremiums between Japan and the European Union were 0.296 (P < 0.001) and 0.066 (P = 0.498), respectively. Those between Japan and the United States were 0.560 (P < 0.001) and 0.281 (P = 0.002), indicating that pediatric drug development in Japan was more active after the introduction of these premiums, even reaching the level of the European Union. The Pediatric Regulation and the Paediatric Committee promoted pediatric drug development in the European Union. The registered number of clinical trials that includes at least 1 participants <18 years old in the European Union Clinical Trials Register increased by 247 trials (from 672) in the 1000 days after regulation. The ratio of pediatric clinical trials with an approved Paediatric Investigation Plan increased to >15% after 2008. Implications: Recruitment and ethical obstacles make conducting pediatric clinical trials challenging. An improved operational framework for conducting clinical trials should mirror the ever-improving regulatory framework that incentivizes investment in pediatric clinical trials. Technological approaches, enhancements in electronic medical record systems, and community approaches that actively incorporate input from physicians, researchers, and patients could offer a sustainable solution to recruitment of pediatric study participants. The key therefore is to improve pediatric pharmacotherapy collaboration among industry, government, academia, and community. Expanding the regulatory steps taken in the European Union, United States, and Japan and using innovative clinical trial tools can move pediatric pharmacotherapy out of its current therapeutic orphan state.

Current Knowledge, Challenges and Innovations in Developmental Pharmacology: A Combined Conect4children Expert Group and European Society for Developmental, Perinatal and Paediatric Pharmacology White Paper

How paediatric drug development and use could benefit from OMICs: A c4c expert group white paper

Paediatric Drug Development and Formulation Design—a European Perspective

Pediatric Drug Development: Reviewing Challenges and Opportunities by Tracking Innovative Therapies

Developmental Changes in Pharmacokinetics and Pharmacodynamics

General Clinical and Methodological Considerations on the Extrapolation of Pharmacokinetics and Optimization of Study Protocols for Small Molecules and Monoclonal Antibodies in Children

New Horizons in Pediatric Psychopharmacology

Safety, dosing, and pharmaceutical quality for studies that evaluate medicinal products (including biological products) in neonates

Points to consider when initiating clinical investigations in autistic paediatric populations-A White Paper

Dosage individualization in children: integration of pharmacometrics in clinical practice

Innovative Study Designs Optimizing Clinical Pharmacology Research in Infants and Children

Challenges in the assessment of adverse drug reactions in children and neonates

Principles and Applications of Pharmacometrics in Drug Evaluation in Children.

Improvement of Pediatric Drug Development: Regulatory and Practical Frameworks

Rationalizing optimal dosing of phytotherapeutics for use in children: Current status - potential solutions - actions needed

No population left behind: Improving paediatric drug safety using informatics and systems biology

Developmental Pharmacokinetics in Pediatric Populations.

Recurrent 17 Bp Duplication in PITX3 is Primarily Associated with Posterior Polar Cataract (CPP4)

Size and Taste Matters: Recent Progress in the Development of Age-Appropriate Medicines for Children

Development of Paediatric Medicines: Key Risk Factors and Non-clinical Research Programmes

Pharmacogenetic Aspects of Drug Metabolizing Enzymes and Transporters in Pediatric Medicine: Study Progress, Clinical Practice and Future Perspectives